Plitidepsin has a safe cardiac profile: A comprehensive analysis

Marine Drugs

Volumn 9, Issue 6, 2011, Pages 1007-1023

  Soto Matos, Arturo ^a   Szyldergemajn, Sergio ^a   Extremera, Sonia ^a   Miguel Lillo, Bernardo ^a   Alfaro, Vicente ^a   Coronado, Cinthya ^a   Lardelli, Pilar ^a   Roy, Elena ^a   Corrado, Claudia Silvia ^a   Kahatt, Carmen ^a  

^a PHARMAMAR S A   (Spain)

Author keywords

Cancer; Cardiac toxicity; Chemotherapy; Plitidepsin; Single agent

Indexed keywords

DEHYDRODIDEMNIN B;

ACUTE HEART INFARCTION; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AREA UNDER THE CURVE; ARTICLE; ATRIOVENTRICULAR BLOCK; CANCER CHEMOTHERAPY; CANCER PATIENT; CARDIOVASCULAR RISK; COLORECTAL CANCER; DEMOGRAPHY; DRUG CLEARANCE; DRUG EXPOSURE; DRUG SAFETY; ELECTROCARDIOGRAM; HEAD AND NECK CANCER; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART FAILURE; HEART MUSCLE ISCHEMIA; HEART PALPITATION; HEART SUPRAVENTRICULAR ARRHYTHMIA; HUMAN; HYPERTENSION; HYPOTENSION; KIDNEY CANCER; LUNG NON SMALL CELL CANCER; LYMPHOMA; MAJOR CLINICAL STUDY; MAXIMUM PLASMA CONCENTRATION; MELANOMA; MONOTHERAPY; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PANCREAS CANCER; PERICARDIAL EFFUSION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; QT INTERVAL; QT PROLONGATION; SIDE EFFECT; SINUS TACHYCARDIA; SOLID TUMOR; SUPRAVENTRICULAR TACHYCARDIA; TACHYCARDIA; THORAX PAIN; THYROID MEDULLARY CARCINOMA; TRANSITIONAL CELL CARCINOMA; VENTRICULAR HYPOKINESIA;

EID: 79959697959     PISSN: None     EISSN: 16603397     Source Type: Journal    
DOI: 10.3390/md9061007     Document Type: Article

References (45)

1. Floyd, J.D.; Nguyen, D.T.; Lobins, R.L.; Bashir, Q.; Doll, D.C.; Perry, M.C. Cardiotoxicity of cancer therapy. J. Clin. Oncol. 2005, 23, 7685-7696. (Pubitemid 46291833)
2. Carver, J.R.; Shapiro, C.L.; Ng, A.; Jacobs, L.; Schwartz, C.; Virgo, K.S.; Hagerty, K.L.; Somerfield, M.R.; Vaughn, D.J. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: Cardiac and pulmonary late effects. J. Clin. Oncol. 2007, 25, 3991-4008. (Pubitemid 47477279)
3. Ewer, M.S.; Lippman, S.M. Type II chemotherapy-related cardiac dysfunction: Time to recognize a new entity. J. Clin. Oncol. 2005, 23, 2900-2902. (Pubitemid 46224107)
4. Seidman, A.; Hudis, C.; Pierri, M.K.; Shak, S.; Paton, V.; Ashby, M.; Murphy, M.; Stewart, S.J.; Keefe, D. Cardiac dysfunction in the trastuzumab clinical trials experience. J. Clin. Oncol. 2002, 20, 1215-1221. (Pubitemid 34177427)
5. Fiuza, M. Cardiotoxicity associated with trastuzumab treatment of HER2+ breast cancer. Adv. Ther. 2009, 26 (Suppl. 1), S9-S17.
6. Lenihan, D.J.; Alencar, A.J.; Yang, D.; Kurzrock, R.; Keating, M.J.; Duvic, M. Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sezary syndrome. Blood 2004, 104, 655-658. (Pubitemid 38970557)
7. Bagnes, C.; Panchuk, P.N.; Recondo, G. Antineoplastic chemotherapy induced QTc prolongation. Curr. Drug Saf. 2010, 5, 93-96.
8. Keefe, D.L. The cardiotoxic potential of the 5-HT(3) receptor antagonist antiemetics: Is there cause for concern? Oncologist 2002, 7, 65-72. (Pubitemid 34151109)
9. Jurcut, R.; Wildiers, H.; Ganame, J.; D'Hooge, J.; Paridaens, R.; Voigt, J.U. Detection and monitoring of cardiotoxicity-what does modern cardiology offer? Support. Care Cancer 2008, 16, 437-445.
10. Rinehart, K.; Lithgow-Berelloni, A.M. Novel antiviral and cytotoxic agent. PCT Int. Pat. Appl. WO 91.04985, 18 April 1991; GB Appl. 89/22,026, 29 September 1989; Chem. Abstr. 1991, 115, 248086q.
11. Depenbrock, H.; Peter, R.; Faircloth, G.T.; Manzanares, I.; Jimeno, J.; Hanauske, A.R. In vitro activity of aplidine, a new marine-derived anti-cancer compound, on freshly explanted clonogenic human tumour cells and haematopoietic precursor cells. Br. J. Cancer 1998, 78, 739-744. (Pubitemid 28418305)
12. Gonzalez-Santiago, L.; Suarez, Y.; Zarich, N.; Muñoz-Alonso, M.J.; Cuadrado, A.; Martinez, T.; Goya, L.; Iradi, A.; Saez-Tormo, G.; Maier, J.V.; et al. Aplidin induces JNK-dependent apoptosis in human breast cancer cells via alteration of glutathione homeostasis, Rac1 GTPase activation, and MKP-1 phosphatase downregulation. Cell Death Differ. 2006, 13, 1968-1981. (Pubitemid 44542409)
13. Garcia-Fernandez, L.F.; Losada, A.; Alcaide, V.; Alvarez, A.M.; Cuadrado, A.; Gonzalez, L.; Nakayama, K.; Nakayama, K.I.; Fernandez-Sousa, J.M.; Munoz, A.; et al. Aplidin induces the mitochondrial apoptotic pathway via oxidative stress-mediated JNK and p38 activation and protein kinase C delta. Oncogene 2002, 21, 7533-7544.
14. Cuadrado, A.; Gonzalez, L.; Suarez, Y.; Martinez, T.; Munoz, A. JNK activation is critical for Aplidin-induced apoptosis. Oncogene 2004, 23, 4673-4680. (Pubitemid 38859456)
15. Muñoz, M.J.; Alvarez, E.; Martinez, T.; Gonzalez-Santiago, L.; Sasak, H.; Lepage, D.; Aviles, P.; Muñoz, A. JNK activation as an in vivo marker of Aplidin® Activity. In Proceedings of the 2007 AACR Annual Meeting, Los Angeles, CA, USA, 14-18 April 2007; Abstract No. 5580.
16. Biscardi, M.; Caporale, R.; Balestri, F.; Gavazzi, S.; Jimeno, J.; Grossi, A. VEGF inhibition and cytotoxic effect of aplidin in leukemia cell lines and cells from acute myeloid leukemia. Ann. Oncol. 2005, 16, 1667-1674. (Pubitemid 41510142)
17. Taraboletti, G.; Poli, M.; Dossi, R.; Manenti, L.; Borsotti, P.; Faircloth, G.T.; Broggini, M.; D'Incalci, M.; Ribatti, D.; Giavazzi, R. Antiangiogenic activity of aplidine, a new agent of marine origin. Br. J. Cancer 2004, 90, 2418-2424. (Pubitemid 38961909)
18. Broggini, M.; Marchini, S.V.; Galliera, E.; Borsotti, P.; Taraboletti, G.; Erba, E.; Sironi, M.; Jimeno, J.; Faircloth, G.T.; Giavazzi, R.; D'Incalci, M. Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine loop in human leukemia cells MOLT-4. Leukemia 2003, 17, 52-59.
19. Straight, A.M.; Oakley, K.; Moores, R.; Bauer, A.J.; Patel, A.; Tuttle, R.M.; Jimeno, J.; Francis, G.L. Aplidin reduces growth of anaplastic thyroid cancer xenografts and the expression of several angiogenic genes. Cancer Chemother. Pharmacol. 2006, 57, 7-14. (Pubitemid 41704919)
20. Faivre, S.; Chieze, S.; Delbaldo, C.; Ady-Vago, N.; Guzman, C.; Lopez-Lazaro, L.; Lozahic, S.; Jimeno, J.; Pico, F.; Armand, J.P.; et al. Phase I and pharmacokinetic study of aplidine, a new marine cyclodepsipeptide in patients with advanced malignancies. J. Clin. Oncol. 2005, 23, 7871-7880.
21. Maroun, J.A.; Belanger, K.; Seymour, L.; Matthews, S.; Roach, J.; Dionne, J.; Soulieres, D.; Stewart, D.; Goel, R.; Charpentier, D.; et al. Phase I study of Aplidine in a dailyx5 one-hour infusion every 3 weeks in patients with solid tumors refractory to standard therapy. A National Cancer Institute of Canada Clinical Trials Group study: NCIC CTG IND 115. Ann. Oncol. 2006, 17, 1371-1378.
22. Izquierdo, M.A.; Bowman, A.; Garcia, M.; Jodrell, D.; Martinez, M.; Pardo, B.; Gomez, J.; Lopez-Martin, J.A.; Jimeno, J.; Germa, J.R.; et al. Phase I clinical and pharmacokinetic study of plitidepsin as a 1-hour weekly intravenous infusion in patients with advanced solid tumors. Clin. Cancer Res. 2008, 14, 3105-3112.
23. Schoffski, P.; Guillem, V.; Garcia, M.; Rivera, F.; Tabernero, J.; Cullell, M.; Lopez-Martin, J.A.; Pollard, P.; Dumez, H.; del Muro, X.G.; et al. Phase II randomized study of Plitidepsin (Aplidin), alone or in association with L-carnitine, in patients with unresectable advanced renal cell carcinoma. Mar. Drugs 2009, 7, 57-70.
24. Eisen, T.; Thatcher, N.; Leyvraz, S.; Miller, W.H., Jr.; Couture, F.; Lorigan, P.; Luthi, F.; Small, D.; Tanovic, A.; O'Brien, M. Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer. Lung Cancer 2009, 64, 60-65.
25. Eisen, T.; Thomas, J.; Miller, W.H., Jr.; Gore, M.; Wolter, P.; Kavan, P.; Martin, J.A.; Lardelli, P. Phase II study of biweekly plitidepsin as second-line therapy in patients with advanced malignant melanoma. Melanoma Res. 2009, 19, 185-192.
26. Dumez, H.; Gallardo, E.; Culine, S.; Galceran, J.C.; Schoffski, P.; Droz, J.P.; Extremera, S.; Szyldergemajn, S.; Flechon, A. Phase II study of biweekly plitidepsin as second-line therapy for advanced or metastatic transitional cell carcinoma of the urothelium. Mar. Drugs 2009, 7, 451-463.
27. Baudin, E.; Droz, J.P.; Paz-Ares, L.; van Oosterom, A.T.; Cullell-Young, M.; Schlumberger, M. Phase II study of plitidepsin 3-hour infusion every 2 weeks in patients with unresectable advanced medullary thyroid carcinoma. Am. J. Clin. Oncol. 2010, 33, 83-88.
28. Peschel, C.; Hartmann, J.T.; Schmittel, A.; Bokemeyer, C.; Schneller, F.; Keilholz, U.; Buchheidt, D.; Millan, S.; Izquierdo, M.A.; Hofheinz, R.D. Phase II study of plitidepsin in pretreated patients with locally advanced or metastatic non-small cell lung cancer. Lung Cancer 2008, 60, 374-380.
29. Mateos, M.V.; Cibeira, M.T.; Richardson, P.G.; Prosper, F.; Oriol, A.; de la Rubia, J.; Lahuerta, J.J.; Garcia-Sanz, R.; Extremera, S.; Szyldergemajn, S.; et al. Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma. Clin. Cancer Res. 2010, 16, 3260-3269.
30. Ferme, C.; Mateos, M.V.; Szyldergemajn, S.; Zucca, E.; Giani, A.M.; Ribrag, V. Plitidepsin Activity in Peripheral T-Cell Lymphoma (PTCL). In Proceedings of T-Cell Lymphoma Forum, Maui, HI, USA, 28-30 January 2010; p. 76.
31. Piekarz, R.L.; Frye, A.R.; Wright, J.J.; Steinberg, S.M.; Liewehr, D.J.; Rosing, D.R.; Sachdev, V.; Fojo, T.; Bates, S.E. Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Clin. Cancer Res. 2006, 12, 3762-3773. (Pubitemid 44000258)
32. Shah, M.H.; Binkley, P.; Chan, K.; Xiao, J.; Arbogast, D.; Collamore, M.; Farra, Y.; Young, D.; Grever, M. Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors. Clin. Cancer Res. 2006, 12, 3997-4003. (Pubitemid 44078086)
33. Strevel, E.L.; Ing, D.J.; Siu, L.L. Molecularly targeted oncology therapeutics and prolongation of the QT interval. J. Clin. Oncol. 2007, 25, 3362-3371. (Pubitemid 47325624)
34. Ciruelos, E.M.; Twelves, C.; Dominguez, M.J.; McKay, H.; Anthony, A.; Castellanos, D.; Bezares, S.; Ruiz, A.; Lopez-Lazaro, L.; Jimeno, J.; et al. Phase I clinical and pharmacokinetic study of the marine compound aplidine (APL) administered as a 3 hour infusion every 2 weeks. Proc. Am. Soc. Clin. Oncol. 2002, 21, 106a, Abstract No. 422.
35. Nalda-Molina, R.; Valenzuela, B.; Ramon-Lopez, A.; Miguel-Lillo, B.; Soto-Matos, A.; Perez-Ruixo, J.J. Population pharmacokinetics meta-analysis of plitidepsin (Aplidin) in cancer subjects. Cancer Chemother. Pharmacol. 2009, 64, 97-108.
36. Roche, B. Exploratory Study of the Effects of Escalating Doses of Aplidin on: RR, QTc, VP/dtmax and dLVP/dtmin in a Guinea Pig Langendorff Preparation; Report SPLG06-00; QTest Labs: Columbus, OH, 2007, unpublished work.
37. RATE Steering Committee; RATE Investigators. Registry of Atrial Tachycardia and Atrial Fibrillation Episodes in the cardiac rhythm management device population: The RATE Registry design. Am. Heart J. 2009, 157, 983-987.e1.
38. Maurer, M.S.; Shefrin, E.A.; Fleg, J.L. Prevalence and prognostic significance of exercise-induced supraventricular tachycardia in apparently healthy volunteers. Am. J. Cardiol. 1995, 75, 788-792.
39. Sanoski, C.A. Prevalence, pathogenesis, and impact of atrial fibrillation. Am. J. Health Syst. Pharm. 2010, 67, S11-S16.
40. Fossa, S.D.; Dearnaley, D.P.; Law, M.; Gad, J.; Newling, D.W.; Tveter, K. Prognostic factors in hormone-resistant progressing cancer of the prostate. Ann. Oncol. 1992, 3, 361-366.
41. Weinstein, S.J.; Mackrain, K.; Stolzenberg-Solomon, R.Z.; Selhub, J.; Virtamo, J.; Albanes, D. Serum creatinine and prostate cancer risk in a prospective study. Cancer Epidemiol. Biomarkers Prev. 2009, 18, 2643-2649.
42. Tessler, D.A.; Catanzaro, A.; Velanovich, V.; Havstad, S.; Goel, S. Predictors of cancer in patients with suspected pancreatic malignancy without a tissue diagnosis. Am. J. Surg. 2006, 191, 191-197. (Pubitemid 43151265)
43. Pronzato, P. Cancer-related anaemia management in the 21st century. Cancer Treat. Rev. 2006, 32 (Suppl. 2), S1-S3.
44. Kishi, S.; Yoshida, A.; Yamauchi, T.; Tsutani, H.; Lee, J.D.; Nakamura, T.; Naiki, H.; Ueda, T. Torsade de pointes associated with hypokalemia after anthracycline treatment in a patient with acute lymphocytic leukemia. Int. J. Hematol. 2000, 71, 172-179.
45. Ng, R.; Better, N.; Green, M.D. Anticancer agents and cardiotoxicity. Semin. Oncol. 2006, 33, 2-14. (Pubitemid 43214484)